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Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, life-threatening disorder characterized by chronic
intravascular hemolysis caused by uncontrolled complement activation. Hepatic vein thrombosis (Budd-Chiari
syndrome) is common in PNH patients. This case report describes the response to eculizumab (a humanized
monoclonal antibody that inhibits terminal complement activation) in a 25-year-old male with progressive liver
function deterioration despite standard anticoagulation therapy and transjugular intrahepatic porto-systemic shunt. The
patient presented with anemia, severe thrombocytopenia, headache, abdominal pain, and distention. He was
diagnosed with PNH, cerebral vein thrombosis, and Budd-Chiari syndrome. Despite adequate anticoagulation, diuretic
administration, and placement of a transjugular shunt, additional thrombotic events and progressive liver damage
were observed. Eculizumab therapy was initiated, resulting in rapid blockade of intravascular hemolysis, increased
platelet counts, ascites resolution, and liver function recovery, all of which are presently sustained. Since starting
eculizumab the patient has had no further thrombotic events and his quality of life has dramatically improved. This is
the first report to confirm the role of complement-mediated injury in the progression of Budd-Chiari syndrome in a
patient with PNH. This case shows that terminal complement blockade with eculizumab can reverse progressive
thromboses and hepatic failure that is unresponsive to anticoagulation therapy and suggests that early initiation of
eculizumab should be included in the therapeutic regimen of patients with PNH-related Budd-Chiari syndrome.
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Paroxysmal nocturnal hemoglobinuria (PNH) is a life-
threatening, progressive, acquired genetic disease char-
acterized by the clonal, nonmalignant expansion of
hematopoietic stem cells deficient in glycosylphosphati-
dylinositol (GPI) synthesis. This deficiency results in
fewer GPI-anchored complement inhibitors (CD55 and
CD59) on the cell surface, causing increased chronic
complement-mediated intravascular hemolysis and
platelet hyperactivation and aggregation [1]. Both pro-
cesses lead to an increased risk of thrombosis, renal dys-
function and damage, pulmonary hypertension, and* Correspondence: albrodsky01@yahoo.com.ar
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reproduction in any medium, provided the oranemia, which, despite historical treatment regimens,
have resulted in up to 35% mortality within 5 years of
diagnosis [2]. Thromboembolism is the most common
cause of PNH-related death, accounting for two-thirds
of all mortalities in patients with this disease [3]. Be-
tween 29% and 44% of PNH patients experience a clinic-
ally evident thromboembolism, affecting the liver, brain,
gut, and kidney [3,4]. Recent registry analyses support
an 8.4- to 15.4-fold increased risk of death in patients
with PNH with thromboembolism [4,5].
Budd-Chiari syndrome (BCS) is common in PNH
patients and anticoagulation therapy is traditionally the
first treatment choice for the management of this disorder.
However, PNH patients frequently experience new throm-
botic episodes despite adequate anticoagulation, which
limits the usefulness of subsequent hepatic vein angio-
plasty and/or stenting and transjugular intrahepatic porto-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cating anticoagulation management, thrombocytopenia
occurs in 25% to 52% of PNH patients, creating a high risk
of severe bleeding [5,8]. Additional therapeutic options for
BCS in patients with PNH are limited to high-risk allogen-
eic hematopoietic stem-cell transplantation or liver trans-
plantation. In one retrospective study in patients with
PNH, there was a 22% reduction in 5-year survival in
patients who had received stem-cell transplantation com-
pared with those who had not [9] while liver transplant-
ation in patients with ongoing intravascular hemolysis due
to PNH has been associated with high rates of thrombotic
and hemorrhagic complications [10].
Eculizumab is a humanized monoclonal antibody that
specifically targets the terminal complement protein C5,
blocking complement-mediated hemolysis. Two multi-
national, phase 3 studies and a related extension study
demonstrated that eculizumab significantly reduces
hemolysis and thrombotic events in patients with PNH
[3,11,12]. These studies also showed that eculizumab
was effective in reducing renal impairment, pulmonary
hypertension, and transfusion requirements, while im-
proving fatigue and quality of life. Furthermore, long-
term treatment with eculizumab has been shown to
normalize survival of patients with PNH compared with
age- and sex-matched controls [6]. Long-term treatment
with eculizumab has demonstrated a favorable safety
profile [3,11-13].
Here, we describe the effect of eculizumab in a patient
with PNH who was being considered for liver trans-
plantation because of multiple thrombotic events, pro-
gressive BCS, and declining liver function.
Case report
In June 2005, a 25-year-old white male was hospitalized
when he presented with progressive headache, emesis,Figure 1 MRI evidence of BCS. (A) T2-weighted MRI. Hepatic veins are no
vessels. (B) Image obtained caudal to (A) shows a normal appearing portalabdominal pain, and abdominal distension. Ascites was
diagnosed and 2500 mL serous liquid was drained via
paracentesis. Physical examination revealed hepatomeg-
aly, splenomegaly, and bilateral papilloedema. Blood ana-
lysis showed a hemoglobin concentration of 9 g/dL
(normal range: 14–18 g/dL), white blood cell count of
3.3 × 109/L (normal range: 4.3–10.8 × 109/L), platelet
count of 19 × 109/L (normal range: 150–400 × 109/L), un-
bound bilirubin concentration of 1.7 mg/dL (normal
range: 0.2–0.8 mg/dL), and lactate dehydrogenase (LDH)
levels of 1684 U/L (upper limit of normal: 480 U/L).
Both Ham and sucrose tests were positive and peripheral
blood flow cytometry confirmed the diagnosis of PNH
with a granulocyte clone size of 95%. Magnetic reson-
ance imaging (MRI) scans showed BCS (Figure 1) and
magnetic resonance angiography (MRA) identified
thromboses of the left transverse and superior sagittal
cerebral sinus veins (Figure 2).
Despite severe thrombocytopenia, the patient received
anticoagulation therapy in the form of subcutaneous
enoxaparin (1 mg/kg every 12 hours) for 80 months.
The patient also received supplemental oral iron and
folic acid and was treated with a short course of corti-
costeroids (methylprednisone, 1 mg/kg/day) to improve
thrombocytopenia. In spite of adequate parenteral antic-
oagulation, BCS progressed and the patient experienced
two symptomatic suprahepatic thromboses, increasingly
refractory ascites, and painful congestive hepatomegaly,
requiring the placement of a TIPS, an immediate splenic
embolization (Figure 3), and an additional course of cor-
ticosteroids to treat severe refractory thrombocytopenia.
A TIPS thrombosis developed and endovascular reper-
meabilization was required to restore TIPS patency suc-
cesfully. A second definitive TIPS thrombosis soon
ensued, which was followed by refractory ascites that
required paracentesis every 2 to 3 weeks, progressivet identified. Notice presence of comma-shaped intrahepatic collateral
vein.
Figure 2 MRA evidence of cerebral vein thrombosis. (A) A complete thrombotic occlusion of the left transverse sinus vein origin is evident
(thick arrow). Collateral circulation (thin arrow) partially fills its proximal portion. (B) Partial thrombotic occlusion of the superior sagittal sinus vein.
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plantation), and two episodes of symptomatic pulmonary
embolism (Figure 4).
Neither anticoagulation nor TIPS placement prevented
further thromboembolisms—the patient experienced two
hepatic thromboses and two pulmonary embolisms over
more than 40 months of therapy—that increased the extent
of liver damage. Therefore, alternative treatment to prevent
complement-mediated thrombosis was explored.
In January 2009, eculizumab (Alexion Pharmaceuticals,
Cheshire, CT) treatment was initiated at the approved dos-
ing regimen: 600 mg weekly for the first 4 weeks, followed
by 900 mg for the fifth dose 1 week later, then 900 mg everyFigure 3 Abdominal computed tomography scan showing a
transjugular intrahepatic portosystemic shunt (arrow) and a
massive splenic infarct as a result of the splenic embolization.2 weeks thereafter. Within 2 weeks of starting treatment
with eculizumab, LDH levels had decreased by 73% from
an average of 2.9-fold above normal 1 to 2 months before
treatment to within normal levels (≤480 U/L). This reduc-
tion was maintained for more than 2.5 years (921 days;
Table 1), the latest data collected for this patient. Platelet
count increased from 23×109/L on day 1 of eculizumab
treatment to 53×109/L, a 130% increase, after 1 week and
was sustained at a level of between 53 and 94×109/L (aver-
age 67×109/L) for 921 days. Rapid improvements in hep-
atic function were also observed, with alanine
aminotransferase and aspartate aminotransferase levels
reduced by 68.3% and 76.9%, respectively, from assessmentsFigure 4 Coronal reconstruction of a pulmonary computed
tomography angiography. An embolus is seen in the lower right
lung artery.
Table 1 Effect of eculizumab on liver function
Days post-
eculizumab
Laboratory value (normal range)
LDH Platelets Hemoglobin AST ALT Bilirubin total Bilirubin D Cholinesterase Albumin
U/L × 109/L g/dL U/L U/L mg/dL mg/dL U/L g/dL
(≤480) (150–400) (14–18) (≤40) (≤37) (0.2–1.3) (<0.3) (>4400) (3.5–5.0)
-68 1836 34 9.2 63 78 3.6 1.7 3572 ─
-33 921 27 9.8 49 70 2.4 0.9 2889 3.47
0 (1st dose) ─ 23 10.7 36 24 3.3 1.4 ─ ─
7 519 53 9.7 20 18 2.3 1 ─ 3.54
14 368 57 10.3 15 14 1.9 0.7 ─ ─
56 565 80 9.6 28 9 2.2 1 5135 3.6
119 248 53 9.9 16 8 1.7 0.8 5975 ─
202 295 94 11.3 25 20 2.1 0.9 6968 4.52
300 344 62 10.3 28 25 1.6 0.6 7603 4.68
365 298 58 10.2 22 19 1.6 0.7 ─ 4.27
449 354 69 11.3 26 26 1.9 0.8 7704 5.1
547 340 63 12 25 24 1.6 0.6 7852 4.73
631 285 73 11.6 26 27 1.8 0.7 8360 ─
743 351 65 11.5 26 23 1.7 0.7 8294 4.46
827 388 64 11.2 26 22 1.4 0.6 ─ ─
921 423 77 12.6 28 25 1.9 0.6 ─ 4.49
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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of eculizumab therapy (Table 1). The significant reductions
in both of these enzymes were sustained over the 921-day
treatment time frame reported in this case study. Over the
same period, total bilirubin level declined by between 36.1%
and 61.1%. The concentration of cholinesterase, a marker
of liver function, improved to within the normal level
within 56 days of treatment initiation, the earliest time at
which this parameter was measured, with a progressive in-
crease thereafter, which is a clear sign of ongoing hepatic
functional recovery. Changes in albumin levels paralleled
those for cholinesterase and are representative of improve-
ments in the synthetic capacity of the liver.
The interval between paracentesis increased progres-
sively, giving a clear indication of a decrease in portal
hypertension. After 7.5 months of eculizumab treatment,
no further ascitic fluid evacuation was required. Diuretics,
beta blockers, and hydrosaline restriction were also stopped
after 2 years of eculizumab treatment. Serial liver MRA
studies showed abundant intrahepatic venous collateral
circulation without recanalization of the hepatic veins
(Figure 5), and development of portal cavernomatosis (evi-
dence of portal vein thrombosis, which appeared after
TIPS thrombosis; Figure 5), paralleled the progressive im-
provement in liver function and hemodynamics. An ultra-
sound study showed a partial recanalization of the
suprahepatic veins, which was unnoticed in MRA studies
due to the low blood flow in the recovered blood vessels(Figure 6). In parallel with the improvement in liver vein
thrombosis, a near-complete recanalization of the cerebral
left transverse venous sinus, as well as partial recanaliza-
tion of the sagittal vein sinus, also took place (Figure 7).
As a consequence of these improvements, plans for liver
transplantation were rescinded.
Following initiation of eculizumab, the patient experi-
enced no new symptomatic thrombotic episodes, had a dra-
matic improvement in fatigue, and did not experience any
clinically significant treatment-related adverse events. Con-
sequently, the patient was able to resume a near-normal
work and social life.
Discussion
This is the first report to confirm the role of complement-
mediated injury in the progression of BCS in a patient with
PNH and its improvement with eculizumab treatment.
Thromboembolism is the most common cause of
PNH-related death, accounting for two-thirds of all mor-
talities in patients with this disease [3]. Between 29%
and 44% of PNH patients experience a clinically evident
thromboembolism, which affects the liver, brain, gut and
kidney [3,4]. This patient was no exception as he devel-
oped 2 hepatic and 2 pulmonary thromboembolisms,
despite 40 months of anticoagulation and TIPS therapy.
Recent registry analyses support an 8.4- to 15.4-fold
increased risk of death in patients with PNH with
thromboembolism [4,5]. Historically, this increased risk
Figure 5 Contrast-enhanced T1-weighted MRI. (A) The axial view
shows morphological changes and heterogeneous enhancement
typical of BCS. A hypervascular nodule is seen consistent with a
regenerative nodule (white arrow). A TIPS also is seen (black arrow).
Notice collateral circulation in the abdominal wall. (B) The coronal
view shows prominent tortuous vascular structures compatible with
cavernomatous transformation of the portal vein.
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cations such as chronic kidney disease, pulmonary
hypertension and anemia, have resulted in up to 35% of
patients with PNH dying within 5 years of diagnosis [2].
The patient is currently receiving eculizumab and since
starting this therapy has not experienced any new throm-
boses. This is consistent with recent large cohort analyses
in the United Kingdom that show that anticoagulation for
primary antithrombotic prophylaxis can be safely discontin-
ued in some patients with PNH who are concurrently re-
ceiving eculizumab [6].
Hepatic dysfunction and deterioration in patients with
PNH may also result, in part, from increased vascular re-
sistance and/or inflammation, as reported in renal and pul-
monary systems [14,15]. For example, chronic complement
activation in PNH can lead to local damage of hepatic and/
or Kupffer cells, subsequent upregulation of adhesion mole-
cules, and release of proinflammatory cytokines, such as
interleukin-1 and -6 [16,17]. In addition, complement-
mediated depletion of the smooth muscle relaxant nitric
oxide has been linked to pulmonary and systemichypertension [15,18], as well as reduction of renal blood
flow and function [14]. These effects are ameliorated by the
inhibition of terminal complement activation by eculizu-
mab, which improves chronic kidney disease in patients
with PNH as early as 12 weeks post-treatment [14] and
reduces the risk of systemic and pulmonary hypertension
[15]. Thus, it is reasonable to suggest that terminal comple-
ment inhibition, besides blocking thrombosis in PNH, may
prevent vasoconstriction and inflammation that affects both
hepatic flow and liver function in PNH patients with BCS.
In addition, patients with PNH who are thrombocytopenic,
including the patient in this case, are at higher risk of
thromboembolism than PNH patients with normal platelet
levels [19]. Eculizumab-mediated improvement of platelet
count reduces the risk of thromboembolism, and may in-
crease the safety of concomitant anticoagulation and/or
subsequent treatment modalities, including allogeneic
hematopoietic stem-cell transplantation or liver
transplantation.
In this case, the patient responded to eculizumab with
a dramatic restoration of hepatic function. The retrac-
tion of a planned liver transplant highlights the remark-
able improvements that this patient experienced, and
bodes well for future PNH cases with similar symptom
presentations.
Eculizumab represents the first treatment for PNH that
effectively inhibits complement-mediated intravascular
hemolysis and prevents subsequent morbidities, including
thromboembolism, renal dysfunction, hypertension, and
poor quality of life. Based on the successful treatment of
this patient with PNH and BCS, together with the antith-
rombotic and also the antihypertensive and anti-
inflammatory benefits of inhibiting terminal complement
activation, we suggest that the treatment algorithm pro-
posed by Hoekstra et al. [20] should be modified to in-
clude terminal complement inhibition with eculizumab as
a primary therapeutic intervention in PNH patients who
present with BCS (Figure 8).
Conclusions
Eculizumab, a humanized monoclonal antibody that tar-
gets the C5 complement protein, is effective at blocking
complement-mediated hemolysis in PNH patients. The
ability of eculizumab to reverse the damaging effects of
BCS confirms the role of complement in the progression
of this disease in PNH patients. The absence of new
thromboses in this patient after receiving eculizumab
supports the application of eculizumab in the treatment
of PNH patients with BCS.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images.
Figure 6 Sonographic images showing improved hepatic venous flow. (A) Ultrasonographic detection of partial recanalization of the right
suprahepatic vein (“narrow pass image”). (B) Ultrasound Doppler evaluation of the right suprahepatic vein showing a continuous flow instead of a
pulsatile signal. This is due to a proximal partial obstruction of the hepatic venous outflow.
Figure 7 Axial and sagittal venous MRA show resolution of left transverse sinus occlusion and partial resolution of sagittal venous
sinus thrombosis.
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Figure 8 Revised treatment recommendations for patients with
BCS and/or PNH. As soon as it is established that BCS is secondary
to PNH, eculizumab should be considered in the treatment
paradigm for these at-risk patients (shaded box indicates proposed
revision to the original Hoekstra algorithm). Adapted from Hoekstra
J, et al. J Hepatol, 2009, with permission from Elsevier [20]. OLT,
orthotropic liver transplant.
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